Overview

  • Product nameAnti-HMW Kininogen antibody
    See all HMW Kininogen primary antibodies
  • Description
    Rabbit polyclonal to HMW Kininogen
  • Tested applicationsSuitable for: ICC/IF, WB, IP, ELISA, RIAmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    HMW Kininogen purified from human plasma

Properties

Applications

Our Abpromise guarantee covers the use of ab79653 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use a concentration of 5 µg/ml.
WB Use a concentration of 20 µg/ml. Predicted molecular weight: 72 kDa.
IP Use at an assay dependent dilution.
ELISA Use a concentration of 3 - 8 µg/ml.
RIA Use a concentration of 3 - 8 µg/ml.

Target

  • Function(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
  • Tissue specificitySecreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.
  • Involvement in diseaseDefects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency) [MIM:228960]. HMWK deficiency is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.
  • Sequence similaritiesContains 3 cystatin domains.
  • Post-translational
    modifications
    Bradykinin is released from kininogen by plasma kallikrein.
    Hydroxylation of Pro-383 occurs prior to the release of bradykinin.
    Phosphorylation sites are present in the extracelllular medium.
    N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.
  • Cellular localizationSecreted > extracellular space.
  • Information by UniProt
  • Database links
  • Alternative names
    • Alpha 2 thiol proteinase inhibitor antibody
    • Alpha-2-thiol proteinase inhibitor antibody
    • BDK antibody
    • BK antibody
    • Bradykinin antibody
    • Fitzgerald factor antibody
    • High molecular weight kininogen antibody
    • HMWK antibody
    • Ile-Ser-Bradykinin antibody
    • Kallidin I antibody
    • Kallidin II antibody
    • Kininogen 1 antibody
    • KNG antibody
    • KNG1 antibody
    • KNG1_HUMAN antibody
    • Low molecular weight growth-promoting factor antibody
    • Williams-Fitzgerald-Flaujeac factor antibody
    see all

Anti-HMW Kininogen antibody images

  • ICC/IF image of ab79653 stained HeLa cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab79653, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

References for Anti-HMW Kininogen antibody (ab79653)

This product has been referenced in:
  • Ramadass M  et al. Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies. J Immunol 192:1220-30 (2014). Read more (PubMed: 24367026) »

See 1 Publication for this product

Product Wall

Application ELISA
Sample Dog Serum (NA)
Specification NA
Blocking step Milk as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 25°C
Type Sandwich (Capture)
Username

Abcam user community

Verified customer

Submitted Feb 10 2011

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"